bcl-6、bcl-2、ki-67蛋白表达与弥漫性大B细胞淋巴瘤临床特征及预后相关因素分析

Clinical charteristic and prognosis of diffuse large B cell lympoma

关键词:  弥漫性大B细胞淋巴瘤  bcl-6  bcl-2  ki-67  预后

Key words:  diffuse large B cell lymphoma  bcl-6  bcl-2  ki-67  prognosis

摘要:

［目的］探讨bcl-6、bcl-2、ki-67蛋白表达与弥漫性大B细胞淋巴瘤（DLBCL）的临床特征及预后之间的关系。［方法］ 采用免疫组化法检测bcl-6、bcl-2、ki-67 3种蛋白在32例DLBCL中的表达，并分析其与患者临床特征及预后的关系。［结果］bcl-6、bcl-2蛋白阳性表达率分别为65.6％和71.9％，ki-67蛋白高表达率为65.6％；bcl-6蛋白表达与Ann Arbor分期相关，bcl-2蛋白表达与LDH、Ann Arbor分期相关；ki-67蛋白表达与年龄、LDH及Ann Arbor分期相关；bcl-6阳性组、阴性组平均生存期分别为54.8月和22.2月，bcl-2阳性组、阴性组平均生存期分别为26.5月和68.1月，ki-67高表达组、低表达组平均生存期分别为26.5月和59.6月； bcl-6阳性组、bcl-2阴性组、Ki-67低表达组预后较好。［结论］bcl-6、bcl-2、ki-67蛋白表达与DLBCL预后有一定相关性，可作为判断DLBCL预后的参考指标。

Abstract:

［Objective］To investigate the ralationship between bcl-6,bcl-2 and ki-67 as well as the clinical features and prognosis of diffuse large B cell lymphoma(DLBCL).［Methods］Immunohistochemistry stain was used to determin the expression of bcl-6,bcl-2 and ki-67.［Results］Positive rates of bcl-6 and bcl-2 were 65.6％and 71.9％,the high expression rate of ki-67 was 65.6％. there was a significant correlationship between the bcl-6 and Ann Arbor stage, bcl-2 had a relationship with LDH and Ann Arbor stage; ki-67 had a relationship with age,LDH and Ann Arborstage; The average survival time of bcl-6 positive group and negative group were 54.8 months and 22.2 months, bcl-2 positive group and negative group were 26.5 months and 68.1 months, ki-67 high-expression group and low-expression group were 26.5 months and 59.6 months;bcl-6 positive,bcl-2 negative,Ki-67 low-expression showed a trend to better the overall survival.［Conclusions］The results suggest a signficant correlationship among bcl-6,bcl-2 ,ki-67 and prognosis. Moreover bcl-6,bcl-2 and ki-67 may be the useful prognostic indicator in diffuse large B cell lymphoma.